BNBXOTCFinance ServicesFiscal year ends September 30
BNB PLUS CORP.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.10−0.01 (-6.67%)
Close on Oct 19, 2026
- Market cap
- $878.33K
- P/E (TTM)
- –
- Dividend yield
- –
BNB PLUS CORP. revenue by segment
By business segment
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic DNA Production Services | $1.83M | $1.46M | $1.29M | $988.12K | $1.04M | $1.11M | $965.26K | $895.35K | $751.64K | $878.39K | $894.57K | $1.07M | 76.6% | +75.8% |
| DNA Tagging and Security Products and Services | $560.21K | $629.63K | $464.49K | $1.15M | $1.31M | $1.41M | $1.46M | $1.22M | $1.13M | $1.27M | $1.13M | $1.15M | 23.4% | -57.1% |
| MDx Testing Services | – | – | – | – | – | $1.27M | $1.31M | $1.32M | $1.51M | $3.36M | $6.97M | $11.15M | – | – |
| Operating income | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA Tagging and Security Products and Services | -$412.57K | -$113.21K | -$798.58K | -$911.14K | -$1.44M | -$2.02M | -$2.10M | -$2.55M | -$3.14M | -$3.45M | -$3.86M | -$3.55M | -71.3% |
| Therapeutic DNA Production Services | -$5.36M | -$7.09M | -$8.53M | -$9.30M | -$5.66M | -$5.24M | -$4.99M | -$4.79M | -$4.91M | -$4.31M | -$4.20M | -$3.79M | -5.4% |
| MDx Testing Services | – | – | – | – | – | -$1.21M | -$1.26M | -$1.49M | -$1.44M | -$1.19M | -$399.74K | $1.21M | – |
By product or service
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $2.33M | $1.94M | $1.48M | $1.42M | $1.37M | $1.42M | $1.26M | $1.07M | $1.03M | $1.10M | $1.01M | $1.22M | 97.4% | +70.6% |
| Service revenues | $61.29K | $150.67K | $348.65K | $712.79K | $1.06M | $1.17M | $1.17M | $1.04M | $848.83K | $1.05M | $1.01M | $996.87K | 2.6% | -94.2% |
| Research and development services | – | – | $257.12K | $375.76K | $441.66K | $449.49K | $381.15K | $311.24K | $274.63K | $350.36K | $373.06K | $421.59K | – | – |
| Supply chain | – | – | $534.17K | $1.15M | $1.38M | $1.48M | $1.46M | $1.21M | $1.08M | $1.13M | $882.75K | $827.60K | – | – |
| Asset marking | – | – | – | – | – | – | – | – | $49.04K | $141.35K | $238.69K | $311.81K | – | – |
| Large Scale DNA Production | – | – | $1.04M | $612.36K | – | – | – | $584.12K | – | – | – | $653.02K | – | – |
| Clinical laboratory service revenues | – | – | – | – | – | $1.20M | $1.31M | $1.33M | $1.52M | $3.36M | $6.97M | $11.15M | – | – |
| Clinical laboratory testing services (over-time) | – | – | – | – | – | $1.18M | $1.29M | $1.29M | $1.47M | $1.81M | $2.42M | $3.54M | – | – |
| Clinical laboratory testing services (point-in-time) | – | – | – | – | – | $15.80K | $22.24K | $32.61K | $47.94K | $1.56M | $4.55M | $7.61M | – | – |
By region
From the segment and revenue-disaggregation notes of Bnb Plus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.